SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0000912282-13-000027
Filing Date
2013-01-11
Accepted
2013-01-11 14:19:22
Documents
4
Period of Report
2013-01-09

Document Format Files

Seq Description Document Type Size
1 lorus_20fa-amdno1.htm 20-F/A 110989
2 EXCLUSIVE LICENSE AGREEMENT DATED APRIL 8, 2008 BETWEEN THE COMPANY AND ZOR PHAR ex4_4.htm EX-4.4 662183
3 NON-EXCLUSIVE LICENSE AGREEMENT DATED MAY 1, 2012 BETWEEN THE COMPANY AND GENENT ex4_7.htm EX-4.7 118902
4 lorus_fig1jpg.jpg GRAPHIC 177235
  Complete submission text file 0000912282-13-000027.txt   1137621
Mailing Address 2 MERIDIAN ROAD TORONTO A6 M9W 4Z7
Business Address 2 MERIDIAN ROAD . TORONTO A6 M9W 4Z7
LORUS THERAPEUTICS INC (Filer) CIK: 0000882361 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 0531
Type: 20-F/A | Act: 34 | File No.: 001-32001 | Film No.: 13525121
SIC: 2836 Biological Products, (No Diagnostic Substances)